Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Watchlist | Portfolio | Dashboard

Contact

Faster, Cleaner, Better.

quotes
- Price Overview
- Performance Report
charts
- Interactive Chart
- Snapshot Chart
technicals
company
analysts
- Earnings Estimates
- Analyst Ratings
financials

Aeon Biopharma Inc (AEON)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] by (Cboe BZX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]

News & Headlines for [[ item.sessionDateDisplayLong ]]

Notes

Alerts

Watch

Help

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 GlobeNewswire - Fri Dec 19, 2025

IRVINE, Calif., Dec. 19, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company seeking accelerated and full-label U.S. market...

AEON Biopharma Announces Execution of Exchange Agreement with Daewoong GlobeNewswire - Mon Dec 15, 2025

- AEON and Daewoong Pharmaceutical have executed definitive documentation to exchange $15 million of notes plus accrued interest into new equity, $1.5 million of new notes due 2030, and a cash-exercise...

AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting Scheduling GlobeNewswire - Thu Nov 20, 2025

- First closing of PIPE resulted in ~$1.79M in proceeds - - FDA BPD Type 2a meeting now scheduled for January 21, 2026 - IRVINE, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc....

AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth GlobeNewswire - Fri Nov 14, 2025

– FDA Type 2a meeting scheduled for November 19, 2025, to review AEON’s analytical development plan and initial data – – Positive biosimilarity data for ABP-450 confirming identical amino-acid...

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 GlobeNewswire - Fri May 23, 2025

AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025 GlobeNewswire - Mon May 19, 2025

AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire - Wed May 14, 2025

AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance GlobeNewswire - Fri Apr 25, 2025

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 GlobeNewswire - Mon Apr 21, 2025

AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer GlobeNewswire - Mon Apr 21, 2025